Abstract: There is provided for novel therapy of sleep apnea that involves administering the drug sultiame to the patient.

Abstract: There is provided for novel therapy of sleep apnea that involves administering the drug sultiame to the patient.

Abstract: A method for treating snoring, sleep apnoea and other forms of sleep disordered breathing involves administration to a patient of a therapeutically effective amount of topiramate over an appropriate period of time, such as a period substantially coinciding with the sleep period of a patient. A useful route of administration is per os. Also disclosed is the use of topiramate for the diagnosis of snoring, sleep apnoea and other forms of sleep disordered breathing.

Abstract: A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof, with the proviso that OSA caused by external mechanical obstruction of the airways, such as by mucus, is excluded. Also disclosed is the use of zonisamide for the manufacture of a medicament useful in the treatment; a protective patch comprising zonisamide and a pharmaceutically acceptable carrier for transdermal or transmucosal administration to a person suffering from OSA; and the use of zonisamide for the manufacture of a diagnostic device, kit or composition for the diagnosis of sleep disordered breathing.

Abstract: A method of treating Restless Legs Syndrome (RLS) comprises the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, in pharmacologically effective combined amounts. Also disclosed is a corresponding use; a pharmaceutical composition comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, and a pharmaceutically acceptable carrier; a package comprising a pharmaceutical composition for per-oral administration comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and a pharmaceutically acceptable carrier and a pharmaceutical composition for per-oral administration comprising iron in a biologically usable form and a pharmaceutical acceptable carrier.

Abstract: A method of treating or preventing snoring, obstructive sleep apnea (OSA) and/or central sleep apnea (CSA) comprises administering a pharmacologically effective amount a salt of acetylhomotaurine (AcHT) such as calcium acamprosate (CA) to a patient. Also disclosed is the use of AcHT and CA for the manufacture of a medicament for treating or preventing snoring, OSA and/or CSA and of a diagnostic device, kit or composition; a protective patch comprising AcHT or CA; and a pharmaceutical composition comprising AcHT or CA and an agent capable of alleviating the effects of snoring OSA and/or CSA, in combined amounts effective in the treatment of snoring OSA and/or CSA, and a carrier.

Abstract: A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof, with the proviso that OSA caused by external mechanical obstruction of the airways, such as by mucus, is excluded. Also disclosed is the use of zonisamide for the manufacture of a medicament useful in the treatment; a protective patch comprising zonisamide and a pharmaceutically acceptable carrier for transdermal or transmucosal administration to a person suffering from OSA; and the use of zonisamide for the manufacture of a diagnostic device, kit or composition for the diagnosis of sleep disordered breathing.

Abstract: A method for treating a patient having Metabolic Syndrome comprising Primary Insulin Resistance and exhibiting lipoprotein aberrations or hypertension comprises administering to said patient human growth hormone or a functional analog thereof in an amount effective for decreasing lipoprotein aberrations or hypertension of said patient.

Abstract: Methods for treating a patient for insulin resistance to decrease the insulin resistance in a patient having Metabolic Syndrome comprising Primary Insulin Resistance and abdominal/visceral obesity comprise administering to the patient growth hormone or a functional derivative thereof in an amount effective for decreasing insulin resistance of the patient.

Abstract: A method for treating a patient having Metabolic Syndrome comprising Primary Insulin Resistance and exhibiting lipoprotein aberrations or hypertension comprises administering to said patient human growth hormone or a functional analog thereof in an amount effective for decreasing lipoprotein aberrations or hypertension of said patient.

Abstract: This invention relates to a method for chronic treatment of obesity wherein a pharmaceutically effective amount of a substance that upon administration to a patient without complete IL-6 deficiency will lead to an increased level of an IL-6 receptor agonist is administered to said patient for reducing adipose tissue mass.